SCHEMBL7614249

SCHEMBL7614249

C1CO[C@H]2CNC[C@H]2N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL476835 1.00
SCHEMBL344353 1.00
SCHEMBL6213747 1.00
SCHEMBL4501561 1.00
SCHEMBL6777764 1.00
SCHEMBL8360967 1.00
SCHEMBL9413931 1.00
Hydrochloric Acid SCHEMBL6211701 0.98 DRD3 (0.32)
Hydrochloric Acid SCHEMBL8332733 0.98 DRD3 (0.32)
Bromide SCHEMBL7614248 0.98 DRD3 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6004956-A CHEMICAL INTERMEDIATES FOR BACTERICIDES BAYER AKTIENGESELLSCHAFT (DE) 1999-12-21 US claimed
EP-0551653-B1 Enantiomeric pure cis-2-oxa-5,8-diazabicyclo (4.3.0)nonanes and process for their preparation BAYER AG (DE) 1999-03-17 EP claimed
EP-0551653-A1 Enantiomeric pure 2-oxa-5,8-diazabicyclo (4.3.0)nonanes and process for their preparation BAYER AG (DE) 1993-07-21 EP claimed
US-20230002408-A1 HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS JANSSEN PHARMACEUTICA NV (BE) 2023-01-05 US disclosed
US-10981887-B2 Benzothiophene estrogen receptor modulators G1 THERAPEUTICS, INC. (US) 2021-04-20 US disclosed
US-20200216406-A1 BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS G1 THERAPEUTICS, INC. (US) 2020-07-09 US disclosed
WO-2012019426-A1 PHTHALAZINONE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF 上海恒瑞医药有限公司 (CN) 2012-02-16 WO disclosed
US-6432948-B1 ANTIULCER AGENTS BAYER AKTIENGESELLSCHAFT (DE) 2002-08-13 US disclosed
EP-0946176-B1 THE USE OF 7-(2-OXA-5,8-DIAZABICYCLO 4.3.0]NON-8-YL)-QUINOLONE CARBOXYLIC ACID AND NAPHTHYRIDON CARBOXYLIC ACID DERIVATIVES FOR MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HELICOBACTER PYLORI INFECTIONS AND ASSOCIATED GASTRODUODENAL DISEASES BAYER AG (DE) 2002-03-27 EP disclosed
US-6133260-A Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases BAYER AKTIENGESELLSCHAFT (DE) 2000-10-17 US disclosed
US-6004956-A CHEMICAL INTERMEDIATES FOR BACTERICIDES BAYER AKTIENGESELLSCHAFT (DE) 1999-12-21 US disclosed
EP-0551653-B1 Enantiomeric pure cis-2-oxa-5,8-diazabicyclo (4.3.0)nonanes and process for their preparation BAYER AG (DE) 1999-03-17 EP disclosed
US-5532364-A FROM A DIHYDROPYRIDINE DERIVATIVE BAYER AKTIENGESELLSCHAFT (DE) 1996-07-02 US disclosed
US-5480879-A ANTIBACTERIAL AGENTS BAYER AKTIENGESELLSCHAFT (DE) 1996-01-02 US disclosed
US-5468742-A Antibacterial agents, feed additives BAYER AKTIENGESELLSCHAFT (DE) 1995-11-21 US disclosed
US-5436334-A Enantiomerically pure 2-oxa-5,8-diazabicyclo[4.3.0]nonanes and process for their preparation BAYER AKTIENGESELLSCHAFT (DE) 1995-07-25 US disclosed
EP-0592868-A1 Quinolonecarboxylic acids BAYER AG (DE) 1994-04-20 EP disclosed
EP-0591808-A1 Quinolonecarboxylic acids BAYER AG (DE) 1994-04-13 EP disclosed
EP-0551653-A1 Enantiomeric pure 2-oxa-5,8-diazabicyclo (4.3.0)nonanes and process for their preparation BAYER AG (DE) 1993-07-21 EP disclosed
EP-0550903-A1 Quinolone- and naphthyridone carboxylic acid derivatives as antibacterial agents BAYER AG (DE) 1993-07-14 EP disclosed